Igny­ta jumps on an FDA ‘break­through’ nod for en­trec­tinib; Ther­mo Fish­er buy­ing Patheon in $7.2B deal

→ Igny­ta has fresh rea­son to fo­cus more on en­trec­tinib, its TRK in­hibitor for the treat­ment of NTRK fu­sion-pos­i­tive tu­mors. The FDA has hand­ed out its break­through ther­a­py des­ig­na­tion for the pro­gram, help­ing ig­nite a surge in its share price ($RXDX, up 11%). The ther­a­py, now in Phase II, should re­ceive open door treat­ment by reg­u­la­tors, now charged with help­ing speed the drug through to an ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER